TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Despite having an impressive product portfolio and established commercial organization, the company has struggled to get their products off the launchpad and through COVID-19 headwinds.

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the appointment of Mark Glickman as the Company's Chief Business Officer. Mr. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles. Mr. Glickman received his MBA in Finance and International Managem

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

LONDON--(BUSINESS WIRE)--Theramex launches Bijuva® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

BOCA RATON, Fla.--(BUSINESS WIRE)--This September, TherapeuticsMD, Inc., an innovative women's healthcare company (NASDAQ: TXMD), is recognizing Menopause Awareness Month, as it aims to empower the 64 million women in the U.S. currently in menopauseii. To celebrate this month and all menopausal women, TherapeuticsMD encourages people to Take Pause and learn about menopause. Many people are aware of common menopause symptoms like hot flashes, which impact 85% of menopausal womeniii, but vulvar a

Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness Month

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system). As a result, CMS established the new HCPCS Level II code J7294 “Segesterone acetate and ethi

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the appointment of Hugh O'Dowd as President. Mr. O'Dowd succeeds John C.K. Milligan, IV, who the Company recently appointed as Chief Executive Officer of its vitaCare Prescription Services business. “I am delighted to welcome Hugh as President of TherapeuticsMD. Hugh has a significant operating and strategic history with both large and small pharmaceutical c

TherapeuticsMD Announces Appointment of Hugh O'Dowd as President

TherapeuticsMD's (TXMD) CEO Rob Finizio on Q2 2021 Results - Earnings Call Transcript

Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 4.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 42.11% year over year to ($0.11), which were in line with the estimate of ($0.11).

Recap: TherapeuticsMD Q2 Earnings

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the second quarter ended June 30, 2021. “We continue to make steady progress in line with our expectations related to ANNOVERA and IMVEXXY driving prescription growth, net margins and broader patient access. Importantly, we are seeing improved access to health care providers for our sales force and expansion of

TherapeuticsMD Announces Second Quarter 2021 Financial Results

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. Conference Call & Audio Webcast Det

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

Although the market did not take favorably to recent Q1 numbers, there were some encouraging trends.

TherapeuticsMD: The Long Road To Profitability

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD submits supplemental NDA to FDA for low-dose Bijuva

TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

BOCA RATON, Fla.--(BUSINESS WIRE)--Sun Sentinel names TXMD as Top Workplace Winner

The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q1 2021 Results - Earnings Call Transcript

TherapeuticsMD Inc (NASDAQ: TXMD) reported a Q1 EPS loss of $0.11 better than the analyst consensus estimate loss of $0.12, as well as an improvement from EPS loss of $0.21 a year ago. Sales of $19.90 million were slightly better than the consensus of $19.77 million.

TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD announces business and financial results for Q1 2021; increases gained in net revenue and net product revenue.

TherapeuticsMD Announces First Quarter 2021 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD presents new ANNOVERA data at 2021 Annual Meeting of American College of Obstetrics and Gynecologists

TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD to hold conference call to discuss Q1 2021 business and financial highlights at 8:30 am ET on Thursday, May 6, 2021

TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021

TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Although sales grew by 30% in the fourth quarter, the market remains disinterested. ANNOVERA remains the key. Management are bullish on what is to come without restrictions in a post-covid world.

TherapeuticsMD: Fighting To Regain Support Above $1.20

TXMD has a market disruptive product called ANNOVERA. However, uptake has not been satisfactory.

TherapeuticsMD: Great Product, But We Are Underwhelmed By Execution

TherapeuticsMD (TXMD) stock is up on Friday after announcing approval for one of its hormone treatments in two parts of Europe. The post TXMD Stock: The News Giving TherapeuticsMD Shares a Shot in the Arm Friday appeared first on InvestorPlace.

TXMD Stock: The News Giving TherapeuticsMD Shares a Shot in the Arm Friday

The stock price of TherapeuticsMD Inc (NASDAQ: TXMD) increased by over 10% pre-market. This is why it happened.

TherapeuticsMD Stock Price Increased Over 10% Pre-Market: Why It Happened

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, and Theramex, a dedicated women's health company, announced that BIJUVE® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom and, from the Federal Agency for Medicines and Health Products (FAMHP) for use in Belgium under BIJUVA®. A “decentralized procedure” (DCP) for the regulatory approval of BIJUVA® in se

TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium

News for TherapeuticsMD Stock (TXMD)